

# Global Shingrix Zostavax Market: Key Trends, Market Share, Growth Drivers, And Forecast For 2025-2034

*Shingrix Zostavax Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED KINGDOM, March 12, 2025  
/EINPresswire.com/ -- Updated 2025  
Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!



The Business  
Research Company

The Business Research Company

How Has the [Shingrix Zostavax Market](#) Developed in Recent Years?

The Shingrix Zostavax market has experienced a steady increase, demonstrating a historic compound annual growth rate (HCAGR) of XX%.



The shingrix (zostavax) market size is expected to see XX (FCAGR) in the next few years. It will grow to \$XX million in 2029 at a compound annual growth rate (CAGR) of XX%.”

*The Business Research  
Company*

□ In 2024, the market was valued at \$XX million.

□ By 2025, this figure is expected to reach \$XX million.

□ Key factors contributing to this growth include:

- o Rising adoption of the vaccine
- o Increased focus on public education campaigns
- o Greater emphasis on preventive healthcare
- o Enhanced patient education and advocacy initiatives
- o Expanded insurance coverage for immunization, improving accessibility

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp>

What Growth Is Expected in the Shingrix Zostavax Market in the Coming Years?

Looking ahead, the Shingrix Zostavax market is projected to continue expanding, supported by a forecast compound annual growth rate (FCAGR) of XX%.

□ By 2029, the market size is expected to reach \$XX million.

□ The anticipated growth is driven by:

- oAn increasing geriatric population
- oA rising number of herpes zoster and chickenpox cases
- oGrowing disease prevalence
- oEnhanced awareness of shingles and its complications

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report>

How Is the Growing Adoption of Vaccination Driving [Shingrix Zostavax Market Expansion](#)?

The increasing global acceptance of vaccination is significantly propelling the growth of the Shingrix Zostavax market. Vaccination plays a crucial role in strengthening the immune system by enabling the body to recognize and fight specific pathogens, thereby enhancing overall health and community protection.

Several factors have contributed to the rising vaccination rates:

- Increased awareness of vaccine effectiveness in disease prevention
- Advances in vaccine development ensuring greater safety and accessibility
- Large-scale public health campaigns promoting immunization
- Strong healthcare infrastructure and global vaccination initiatives

Shingrix Zostavax is particularly effective in shielding against shingles and its complications, offering essential protection for individuals over 50. Notably, in May 2024, a study published by the Journal of the American Medical Association (JAMA) revealed a 46% rise in shingles vaccinations covered by Medicare Part D following the implementation of the IRA policy in January 2023.

Who Are the Leading Companies in the [Shingrix Zostavax Global Market](#)?

Prominent players such as GSK plc are at the forefront of this market. GSK plc maintains a strong industry presence, leveraging its innovative product portfolio and market expertise to sustain its leadership.

What Key Trends Are Emerging in the Market?

One notable trend in the Shingrix Zostavax market is the introduction of advanced non-live, recombinant subunit adjuvanted vaccines. These formulations are designed to enhance vaccine efficacy while mitigating the effects of age-related immune decline in vulnerable populations.

- In September 2024, GSK plc launched the shingles vaccine Shingrix.
- The vaccine has gained widespread recognition for its high efficacy.
- Clinical results indicate a 97% effectiveness in preventing shingles and post-herpetic neuralgia.

How Is the Market Segmented?

The Shingrix Zostavax market is categorized into the following segments:

1.By Formulation:

- oRecombinant Vaccine (Shingrix)
- oLive Attenuated Vaccine (Zostavax)

2.By Indication:

- oShingles Prevention
- oPost-Herpetic Neuralgia
- 3.By Distribution Channel:
  - oHospital Pharmacies
  - oRetail Pharmacies

#### How Is the Market Distributed Geographically?

- In 2024, North America emerged as the dominant regional market.
- Asia-Pacific is forecasted to be the fastest-growing region in the upcoming years.
- Additional regions covered in the market report include:
  - oWestern Europe
  - oEastern Europe
  - oSouth America
  - oThe Middle East
  - oAfrica

#### Browse Through More Similar Reports By The Business Research Company:

Human Immunodeficiency Virus (HIV) Diagnosis Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-hiv-diagnosis-global-market-report>

Immunoglobulin E (IgE) Allergy Blood Tests Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/immunoglobulin-e-ige-allergy-blood-tests-global-market-report>

Immunomodulator Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/immunomodulator-global-market-report>

#### Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

#### Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: [https://twitter.com/tbrc\\_info](https://twitter.com/tbrc_info)

YouTube: [https://www.youtube.com/channel/UC24\\_f10rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ)

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/792882456>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.